Comparison of effectiveness of levocloperastine and dextrometorphan in treatment of dry cough

Efficacy and safety of levocloperastine and dextrometorphan in patients with acute dry cough: a randomized open label phase IV clinical trial

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2019/04/018787

Enrollment

Registered

2019-04-25

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J988- Other specified respiratory disorders

Interventions

Intervention1: Levocloperastine: Patients will be administered syrup levocloperastine (20mg/5ml) (Lupin Ltd,Mumbai, India) 5ml thrice daily orally for 7 days Control Intervention1: Dextromethorphan: P

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients with dry cough will be included in the study

Exclusion criteria

Exclusion criteria: 1. Age out of range, 2. Patients regularly using any anti-cough medications 3. Patients with comorbid respiratory, cardiovascular and psychiatric conditions 4. Coadministration of drugs that are likely to interact with levocloperastine or dextromethorphan

Design outcomes

Primary

Measure	Time frame
Change in severity of cough.Timepoint: 14 days	—

Secondary

Measure	Time frame
1. The frequency of cough since last 24 h will be recorded on a 7-point Likert scale. 2. The Quality of Life (QoL) will be assessed using 19-item patient-reported Leicester Cough Questionnaire (LCQ).Timepoint: 14 days	—

Countries

India

Contacts

Public ContactArijit Ghosh

Malda Medical College

drarijitghosh@gmail.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026